Long-term safety and tolerability of oral testosterone (LPCN 1021) in hypogonadal men: Results from the 52-week phase 3 study (soar trial)

Authors
Category Primary study
JournalEndocrine Reviews
Year 2016
This article has no abstract
Epistemonikos ID: 2fd925b527bf7372b5b45ee8689b7da298e7f2c7
First added on: Feb 08, 2025